Xeris Pharmaceuticals Gets $41M In Series C

Austin-based Xeris Pharmaceuticals annnounced Thursday afternoon that it has raised $41M in a Series C funding round, for its injectable drugs for treat hypoglycemia. The funding was led by Redmile Group, and also included Deerfield Management, Sabby Management, The McNair Group, and others. Robert C. Faulkner of Redmile joins the company's board as a result of the funding.